ANTX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-11

• In July, the Company held a pre-IND meeting with the FDA and now plans to expand the Phase 2 study (EBO-PV-201) to add sites in the U.S. and Australia, with an IND filing expected in the third quarter of 2026. As a result of this expansion, Phase 2 enrollment is anticipated to commence in the fourth…

• We are studying AN2-502998 (formerly known as AN15368), an oral, boron-based small molecule CPSF3 inhibitor for the treatment of chronic Chagas disease, also known as American trypanosomiasis. Chagas disease is caused by the parasite Trypanosoma Cruzi (“T. cruzi”). Over 300,000 people are estimated …

• In June 2026, we announced positive results from two studies that we believe support the planned initiation later this year of a Phase 2 trial of AN2-502998 in chronic Chagas disease. In the non-human primate (“NHP”) efficacy study, 28 days of treatment with AN2-502998 resulted in 100% parasitic eli…

• AN2-502998 is the only compound of which we are aware to have demonstrated curative activity in preclinical studies across multiple species, including in NHPs with long-term, naturally acquired chronic infections caused by diverse T. cruzi genetic types. We believe that efficacy in naturally infecte…

• We expect to initiate a Phase 2 proof-of-concept study in adults with chronic Chagas disease in late 2026.

Text removed vs the prior filing · source: 10-Q · 2026-05-11

• We are proceeding through the regulatory process and anticipate initiating the Phase 2 trial in the third quarter of 2026. We expect to provide periodic data readouts beginning as early as the fourth quarter of 2026 and throughout 2027, subject to regulatory clearance and enrollment progress.

• In March 2026, we completed dosing all cohorts in our Phase 1 first-in-human trial of oral AN2-502998 (formerly known as AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease, or American trypanosomia. In the second quarter of 2026, we an…

• We are prioritizing targets in oncology and bone disorders where we believe boron chemistry may offer a competitive advantage in terms of binding-site differentiation, pharmacodynamics, drug-like properties and IP, including initially ENPP1 and PI3Kα. The unique binding modes of boron-containing com…

• Comparison of the Three Months Ended March 31, 2026 and 2025

• Research and development expenses were $6.7 million for the three months ended March 31, 2026 compared to $7.7 million for the three months ended March 31, 2025. The decrease of $1.0 million was primarily due to decreases in chemistry manufacturing and controls (“CMC”) expenses and license fees, par…

Text added vs the prior filing · source: 10-Q · 2026-08-11

• On April 23, 2026, MGC Venture Partners QP 2018, LP, for which one of our directors is a managing director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 652,573 shares of our common stock until August 16, 2027.

• During the fiscal quarter ended June 30, 2026, none of our other directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted, modified, or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended…

Text removed vs the prior filing · source: 10-Q · 2026-05-11

• During the fiscal quarter ended March 31, 2026, none of our other directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted, modified, or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intende…